Immunic Reports Interim Data From Phase 2 CALLIPER Trial Of Vidofludimus Calcium In Progressive Multiple Sclerosis
Portfolio Pulse from Benzinga Newsdesk
Immunic has reported interim data from its Phase 2 CALLIPER trial of Vidofludimus Calcium in progressive multiple sclerosis. The 24-week data shows improvements in biomarker NfL across the overall patient population and all subtypes. The data also reinforces Vidofludimus Calcium's neuroprotective potential. Full brain volume data from the 467 patient cohort is expected in April 2025. The Phase 3 ENSURE program in relapsing multiple sclerosis is ongoing.
October 09, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunic's positive interim data from the Phase 2 trial of Vidofludimus Calcium could boost investor confidence in the company's ongoing research and development efforts.
Positive interim data from a clinical trial often leads to increased investor confidence in a biotech company's ongoing research and development efforts. This could potentially lead to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100